Transcept Pharmaceuticals Announces Expected FDA Extension Of Regulatory Review Period For Intermezzo(R)
June 13th, 2009 Posted in Medical Information, Sleep / Sleep Disorders / Insomnia
Similar Posts
- Transcept Pharmaceuticals Receives Complete Response Letter From FDA On Intermezzo(R) New Drug Application
- Transcept Pharmaceuticals Scheduled To Meet With FDA To Discuss Intermezzo(R) Complete Response Letter
- Transcept Pharmaceuticals Submits New Drug Application For Intermezzo(R) For Treatment Of Middle-of-the-Night Awakenings
- Clinical Study Of Intermezzo(R) For The Treatment Of Middle Of The Night Awakening Published In SLEEP
- Somaxon Announces FDA Approval Of Silenor(R) (doxepin) For The Treatment Of Insomnia